NCT05322408View on ClinicalTrials.gov

HCW9218 in Select Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

January 2, 2025

Study Completion Date

February 28, 2026

Conditions

Solid Tumor

Interventions

DRUG

HCW9218

HCW9218 at the assigned dose level is administered as a subcutaneous injection once every 3 weeks for a minimum of 2 treatment cycles unless medically contraindicated.

Trial Locations (1)

55455

Masonic Cancer Center - University of Minnesota, Minneapolis

All Listed Sponsors

lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT05322408 - HCW9218 in Select Advanced Solid Tumors | Biotech Hunter | Biotech Hunter